11-Jun-2020 | Facts and Factors
Findings from Facts and Factors report “Anticoagulants Market By Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), and By Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global Anticoagulants market in 2019 was approximately USD 27 billion. The market is expected to grow above a CAGR of 7.8% and is anticipated to reach over USD 44 billion by 2026.
Anticoagulant drugs help prevent blood clots and are prescribed to people at higher risk of getting clots. Anticoagulants are less likely to experience serious conditions such as heart attacks and strokes. The production of blood clots, known as blood-thinning drugs, is disrupted by anticoagulants. When blood coagulation prevents blood flow through a blood vessel, the affected component will cease functioning properly. Deep venous thrombosis (DVT), heart attacks, can lead to severe medical conditions such as strokes. Novel oral anticoagulants (NOACs), Vitamin K antagonists, and Low Molecular Heparin (LMWH) are the most common forms of anticoagulants. In recent years, new oral anticoagulants (NOACs) have become immensely common because of their many advantages. For extended anticoagulation therapy, vitamin K antagonists are prescribed. Low molecular heparin (LMWH) allows for ambulatory treatment of diseases, such as lung embolism, deep vein thrombosis, etc.
Browse the full “Anticoagulants Market By Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), and By Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others) : Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/anticoagulants-market-by-drug-class-noacs-heparin-lmwh-1127
Increased occurrences of chronic and cardiovascular disease, increased acceptability of novel oral anticoagulants (NOACs) and increased knowledge of the use of NOACs, increased population aging, lack of specific anticoagulant alternatives, advantageous government policies, and an increasing number of obese individuals are key drivers of this problem. Increased investment by leading market players in developing new products and offering solutions to meet high patient requirements would give market players in the anticoagulant industry new opportunities for development. However, the high cost of NOACs, the existence of alternative medicines, strict government control, risk of side effects, and complications in oral anticoagulants may restrict the global demand for anticoagulants.
NOACs segment is a major revenue-generating segment on the anticoagulants market in 2019 based on drug class and is expected to show dominance over the forecast period, owing to growing NOAC adoption in developing countries and increased use of NOACs over warfarin.
By application, atrial fibrillation predominated in the market in 2019, and due to the large population and increasing use of anticoagulants in the diagnosis of such conditions, it is projected to dominate throughout the forecast period.
The Region of Asia-Pacific offers lucrative opportunities for players working on the anticoagulant market given the growing population base, increased prevalence, and VTE diseases, developing economies, improved diagnostic levels and increasing demand for optimal treatments.
Top Market Players
Top key players operating in the market are Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Portola Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline, Sanofi S.A., Pfizer Inc., Johnson & Johnson, and Others.
This report segments the Anticoagulants market as follows:
Global Anticoagulants Market: By Drug Class Segmentation Analysis
- Heparin & LMWH
- Vitamin K Antagonist
Global Anticoagulants Market: By Application Segmentation Analysis
- Atrial Fibrillation
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
Global Anticoagulants Market: Regional Segmentation Analysis
- North America
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
Level 8, International Finance Center, Tower 2,
8 Century Avenue, Shanghai,
Postal - 200120, China
Tel: +86 21 80360450